Timo M. Siitonen
Oulu, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.
Journal: British journal of haematology
Published: March 05, 2026
Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy.
Journal: HemaSphere
Published: June 24, 2025
Switching From Standard to Extended Half-Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: January 23, 2025
Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial.
Journal: The Lancet. Haematology
Published: December 15, 2024
Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial.
Journal: Basic & clinical pharmacology & toxicology
Published: November 18, 2024
The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia.
Journal: Blood
Published: December 15, 2022
Impact of the number of cryopreserved CD34+ cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: Experience from the GOA study.
Journal: Journal of clinical apheresis
Published: July 08, 2022
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.
Journal: Haematologica
Published: June 30, 2022
Last Updated: 09/26/2026